Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms ABP 130, ABP-130 |
Target |
Action stimulants, inhibitors |
Mechanism CD3 stimulants(T cell surface glycoprotein CD3 stimulants), CEA inhibitors(Carcinoembryonic antigen inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization |
Drug Highest PhaseDiscontinuedPreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Colorectal Cancer | Preclinical | United States | - | |
| Non-Small Cell Lung Cancer | Preclinical | United States | - |






